Rheumatoid Arthritis Research and Therapies

Moving in medRxiv, Gastroenterology, bioRxiv, Communications Biology, Gut, Nature Immunology, Nature Reviews Drug Discovery and The lancet. Gastroenterology & hepatology.

Moved, week to 23 Oct 2026: 0
Papers in 60 days: 11

Add Rheumatoid Arthritis Research and Therapies as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest

Rebuilt 23 October 2026 at 2:52 pm AEDT

Moved this week

Everything that moved →

Nothing in this topic has moved yet this week.

Latest in Rheumatoid Arthritis Research and Therapies

Newest first · last 60 days

Selective inhibition of IL-6 trans-signalling reveals distinct mechanisms of human classic and trans-signalling receptor-complex formation.
Communications Biology · 14 Oct 2026 · Journal Article
A human-specific antibody selectively inhibits interleukin-6 trans-signalling while preserving classic signalling, revealing distinct receptor assembly mechanisms.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42875473
Open in JClub
Optimal Duration of Antibiotic Treatment for Group A Streptococcal Pharyngitis in Children: A Systematic Review and Dose-Response Meta-Analysis
medRxiv · 8 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.06.25.26356472
Open in JClub
Detecting change-points in preclinical rheumatoid arthritis biomarkers using Bayesian multivariate segmented regression
medRxiv · 5 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.05.22.26353892
Open in JClub
Immune-mediated rheumatoid arthritis: from single-cell genomics to new therapies.
Nature Immunology · 1 Oct 2026 · Review
Single-cell genomics has identified pathogenic lymphocyte, myeloid, and fibroblast cell subsets in immune-mediated rheumatoid arthritis.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42675115
Open in JClub
Accuracy of diagnostic codes and algorithms used to identify connective tissue diseases in electronic health records and administrative databases: systematic review and meta-analysis.
medRxiv · 25 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.09.23.26363795
Open in JClub
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.
Nature Reviews Drug Discovery · 23 Sept 2026 · Review
Selective targeting of IL-6 trans-signalling may improve safety and efficacy in treating inflammatory diseases by differentiating from classic signalling pathways.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42778654
Open in JClub
Differential histone tail citrullination by protein arginine deiminases observed via NMR spectroscopy
bioRxiv · 17 Sept 2026 · Preprint
Read the AI summary in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.05.01.722238
Open in JClub
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: 2026 Update.
Gastroenterology · 17 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42753988
Open in JClub
The Cumulative Hazard of Adalimumab De-Escalation: Lessons From the 3-Year LADI Follow-Up.
Gastroenterology · 16 Sept 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42748979
Open in JClub
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
Gut · 7 Sept 2026 · Meta-Analysis
Adding peg-IFN to nucleos(t)ide analogue therapy achieves HBsAg loss in up to 38% of chronic hepatitis B patients with low initial HBsAg levels.
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41198171
Open in JClub
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Randomized Controlled Trial
Duvakitug demonstrated a significant endoscopic response in 48% of patients with Crohn's disease, with the 900 mg dose exceeding placebo response rates in a phase 2b trial.
- 4 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42462749
Open in JClub

Add Rheumatoid Arthritis Research and Therapies as an interest in JClub

Journals this month

All journals →

Topics moving, week to 23 Oct 2026

All topics →

By field

All journals by field →

Moved this week

Latest in Rheumatoid Arthritis Research and Therapies

Browse JClub